The estimated Net Worth of Iv, Llcsv Life Sciences Fun... is at least 25.1 百万$ dollars as of 10 June 2015. Iv Fun owns over 1,119,000 units of Ocular Therapeutix Inc stock worth over 515,549$ and over the last 9 years Iv sold OCUL stock worth over 24,618,000$.
Iv has made over 1 trades of the Ocular Therapeutix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Iv sold 1,119,000 units of OCUL stock worth 24,618,000$ on 10 June 2015.
The largest trade Iv's ever made was selling 1,119,000 units of Ocular Therapeutix Inc stock on 10 June 2015 worth over 24,618,000$. On average, Iv trades about 1,119,000 units every 0 days since 2015. As of 10 June 2015 Iv still owns at least 61,084 units of Ocular Therapeutix Inc stock.
You can see the complete history of Iv Fun stock trades at the bottom of the page.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over 73,512,800$ worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth 38,632,070$ . The most active insiders traders include Management Inc. Opaleye、Road Llc Summer、Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of 999,228$. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth 16,525$.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: